Real-World Incidence and Management of Immune-Related Adverse Events from Immune Checkpoint Inhibitors: Retrospective Claims-Based Analysis

Abstract

Purpose

We assessed real-world spectrum and patterns of irAEs for patients treated with anti-PD(L)1 ICIs.

Methods

irAEs were defined using medical and pharmacy claims for patients enrolled in a Medicare Advantage Prescription Drug plan who initiated treatment with anti-PD(L)-1 and received ≥ 1 dose of therapy between 1 September 2014 and 28 February 2018.

Results

Treatment was discontinued for 46.6% of patients, and withheld and subsequently restarted for 10.3%. While toxicity profiles did not differ by age, RiskRx-V co-morbidity index was higher in patients with irAEs.

Conclusion

These data underscore the needs for tailored irAE diagnostic and management pathways.

Keywords:

• Therapy
• treatment
• cancer in the elderly

Previous presentations

Presented in part at the National Comprehensive Cancer Network Annual Conference, Orlando, Florida, March 20–22, 2019 (Poster Presentation).

Declaration of interest

J.N.: Research Funding: Merck, AstraZeneca; Consulting: AstraZeneca, Bristol Myers-Squibb, Roche/Genentech; Honoraria: AstraZeneca, Bristol Myers-Squibb

Additional information

Funding

Monica Nicosia, PhD, Nicosia Medical Writer LLC, and Mary Costantino, PhD provided medical editing and writing support, funded by Humana Inc.